RITUXIMAB IN REFRACTORY SLE: 10 YEARS AFTER
Bibliographic record
Abstract
PV275 / #231 Poster Topic: AS24 - SLE-Treatment Background/Purpose The aim of this cross-sectional study of patients with refractory SLE treated with RTX was to explore for any potential long-term effect(s) of this B cell depletion approach. Methods We included patients with SLE having had i) received at least 1 cycle of RTX and ii) at least 10yr of follow-up after their first RTX infusion. Response was assessed at 1 year and at their latest evaluation that was ³ 10yr after RTX treatment initiation. In cases where the cSLEDAI-2k was employed, a response was defined as a cSLEDAI-2k of less than 4 in cases were the cSLEDAI-2k was ³ 4. In cases where the cSLEDAI-2k was 2-4 at baseline, a response was defined as a cSLEDAI-2k of 0. For cases of lupus nephritis, a complete response was defined as a proteinuria of < 500 mg/24h and an eGFR 60 ml/min; a partial response was defined as a reduction of the proteinuria of > 50% of baseline values and an eGFR 60 ml/min. In cases of lung involvement, a response was defined as an FVC decline £ 5% predicted values. Results RTX was administered in 62 patients with SLE treated at the 2 Rheumatology tertiary care centers of southwestern Greece. For this cross-sectional study we enrolled 23 patients (25 cases) with SLE (all Caucasian female, age range: 14 – 72yr, mean: 31yr) with active or relapsing disease, fulfilling inclusion criteria. The median disease duration was 6yr (range: 2mo-27yr) at the time of the first RTX treatment infusion. Clinical manifestations at the time of RTX introduction included lupus nephritis in 8 patients, arthritis in 6, neuropsychiatric involvement in 4, vasculitis in 2, lung involvement in 3 and hematological abnormalities in 3. RTX was also administered in 1 patient with lupus hepatitis and in 1 plasmapheresis-plus-steroid resistant case of thrombotic thrombopenic purpura. RTX treatment was associated with a clinical benefit in 82.14% of our patients after 1yr and in 74.48% after ³10yr. The median cSLEDAI-2K score decreased from 5.83 ± 3.70 at baseline to 1.95 ± 2.40 (p < 0.001) at 1yr and to 2.37 ± 3.00 (p < 0.001) at the ³10yr timepoint of follow-up. Ten out of our 23 patients relapsed. The earliest relapse was seen at 6mo and the latest at 13yr after RTX treatment introduction. Eight relapsed patients were re-treated with RTX and 3/8 re-responded. The mean daily dose of corticosteroids was reduced both at the 1yr and at the ³ 10yr time points; dose reductions were not statistically significant. Regarding safety we report 1 COVID19-related death, viral infections in 2, allergic reactions in 4 and 1 patient with late-onset neutropenia. Conclusions Our data suggest that RTX may indeed represent an alternative therapeutic option in patients with SLE refractory to standard treatment with an acceptable safety profile and a potential long-term beneficial effect.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".